Search reports.
NTRK Fusion Gene Positive Advanced Solid Tumors Market Size [2031]
Get free sample report Request for Customiztion Buy Now

NTRK Fusion Gene Positive Advanced Solid Tumors Market Size [2031]

Segments - NTRK Fusion Gene Positive Advanced Solid Tumors Market by Type (Diagnostics and Therapeutics), Application (Cancer Centers, Hospitals, Clinics, and Others), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vaibhav
Fact-checked by : V. Chandola
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-5692 | 4.8 Rating | 68 Reviews | 167 Pages | Format : PDF Excel PPT

Report Description


NTRK Fusion Gene Positive Advanced Solid Tumors Market Outlook 2031

The Global NTRK Fusion Gene Positive Advanced Solid Tumors Market size was valued at USD 120 million in 2022 and is likely to reach USD 220 million by 2031, expanding at a CAGR of 5.9% during 2023 – 2031. The growth of the market is attributed growing number of patients with NTRK fusion gene-positive tumors.

Increasing number of people affected by cancer is resulting in the growing demand for innovative and targeted treatments which further boosts the NTRK fusion gene-positive advanced solid tumors market. NTRK fusion gene-positive tumors represent a distinct subset of cancer with a specific genetic abnormality. These tumors are relatively rare but can occur in various parts of the body.

  • According to a report published by the World Health Organization (WHO) on February 3, 2022, cancer is the leading cause of death globally. In 2020, it was responsible for nearly 10 million deaths, accounting for approximately one in six deaths worldwide. The most common types of cancer are lung, colon, breast, rectal, and prostate cancers.

    NTRK Fusion Gene Positive Advanced Solid Tumors Market Outlook

NTRK fusion gene-positive advanced solid tumors refer to a specific type of cancer that is characterized by the presence of a genetic abnormality known as an NTRK fusion gene. These tumors have certain genes called NTRK genes that fused together leading to the production of abnormal proteins that increase the growth of cancer cells. These tumors occur in various organs and tissues in the body, such as the lungs, thyroid, and colon.

The research report finds that the COVID-19 pandemic hampered the market. The pandemic diverted healthcare resources and attention toward managing the immediate crisis. This has affected the diagnosis, treatment, and research related to NTRK fusion gene-positive tumors. Additionally, clinical trials and research in the field of oncology have been impacted by the pandemic, resulting in slowing down the development of new therapies and treatment strategies for these tumors.

Artificial Intelligence (AI) Impact on NTRK Fusion Gene Positive Advanced Solid Tumors Market

The emergence of artificial intelligence is boosting the market. AI-powered algorithms analyze medical images and genetic data with remarkable precision aiding in the early detection of NTRK fusion gene-positive tumors. Additionally, AI is accelerating research efforts by analyzing vast datasets and identifying patterns for the development of new tumor medicines.

NTRK Fusion Gene Positive Advanced Solid Tumors Market Dynamics

Major Drivers

Rising demand for personalized and tailored treatments is expected to drive the market. Changing lifestyles and environmental factors contribute to a high prevalence of cancer diagnoses, including NTRK fusion gene-positive tumors. This increase in cases drives the demand for specialized treatments tailored to these specific genetic subtypes fueling the market.

  • According to a report published by the National Library of Medicine in January 2023, approximately 1958310 individuals were diagnosed with cancer and around 609820 individuals died due to their cancerous conditions.

Existing Restraints

Lack of skilled laboratory technicians is expected to hamper the market. The shortage of skilled technicians leads to the delays in diagnosing patients with NTRK fusion gene-positive tumors. Additionally, limited awareness among healthcare providers and diagnostic challenges in identifying NTRK fusion gene-positive tumors hinders the market.

Emerging Opportunities

Ongoing innovations in genetic testing and cancer diagnostics technologies are expected to create immense opportunities for the players competing in the market. These advancements lead to early and accurate diagnoses, allowing for prompt initiation of targeted therapies and potentially improving patient outcomes. Furthermore, increasing investment of pharmaceutical companies toward clinical research and trials is propelling the market.

NTRK Fusion Gene Positive Advanced Solid Tumors Market Dynamics

Scope of the NTRK Fusion Gene Positive Advanced Solid Tumors Market Report

The report on the market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

NTRK Fusion Gene Positive Advanced Solid Tumors Market- Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2022

Historic Data

2016–2021

Forecast Period

2023–2031

Segmentation

Type (Diagnostics and Therapeutics) and Application (Cancer Centers, Hospitals, Clinics, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Bayer AG; DAIICHI SANKYO COMPANY, LIMITED; Deciphera Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Glaxosmithkline plc; Merck & Co., Inc.; Pfizer Inc.; and Plexxikon;

 

NTRK Fusion Gene Positive Advanced Solid Tumors Market Segment Insights

Type Analysis

Based on type, the NTRK fusion gene positive advanced solid tumors market is divided into diagnostics and therapeutics. The diagnostics segment is expected to hold a major market revenue share of the market during the forecast period due to the increasing number of patients suffering from NTRK fusion gene-positive advanced solid tumors.

Diagnostics are crucial for identifying NTRK fusion gene-positive tumors, as these tumors have specific genetic alterations involving the fusion of NTRK genes. Moreover, diagnosing enables early-stage tumors detection for achieving favorable treatment outcomes, which further boosts the segment.

NTRK Fusion Gene Positive Advanced Solid Tumors Market Types

Application Analysis

On the basis of application, the market is classified as cancer centers, hospitals, clinics, and others. The hospitals segment is anticipated to register robust growth in the coming years, as they are equipped with advanced diagnostic facilities, including rare disease genetic testing and molecular diagnostics laboratories.

These facilities are essential for accurately identifying NTRK fusion gene-positive tumors. Furthermore, hospitals offer specialized treatments to cater to a wide range of solid tumors, which further fuels the segment.

Regional Outlook

In terms of region, the global NTRK fusion gene positive advanced solid tumors market is segmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market due to the presence of leading research institutions and pharmaceutical companies.

These companies are at the forefront of developing targeted therapies and conducting clinical trials for these specific tumors. Additionally, growing population suffering from solid tumor conditions propels the market in this region.

  • According to the American Cancer Society, approximately 1.9 million new patients diagnosed with cancer in the US in 2022.

The market in Asia Pacific is anticipated to expand at a rapid pace in the coming years due to rising in cancer incidence, including NTRK fusion gene-positive tumors. Factors, such as lifestyle changes, increased life expectancy, and environmental factors fuel the market in the region. This larger patient pool creates a growing market for specialized treatments thrusting market growth.

NTRK Fusion Gene Positive Advanced Solid Tumors Market Regions

Segments

The global NTRK fusion gene positive advanced solid tumors market has been segmented on the basis of

Type

  • Diagnostics
  • Therapeutics

Application

  • Cancer Centers
  • Hospitals
  • Clinics
  • Others

Region

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Bayer AG
  • DAIICHI SANKYO COMPANY, LIMITED
  • Deciphera Pharmaceuticals, Inc
  • F. Hoffmann-La Roche AG
  • Glaxosmithkline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Plexxikon

Competitive Landscape

Key players competing in the global NTRK fusion gene positive advanced solid tumors market are Bayer AG; DAIICHI SANKYO COMPANY, LIMITED; Deciphera Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Glaxosmithkline plc; Merck & Co., Inc.; Pfizer Inc.; and Plexxikon;

These companies are increasing their market share by adopting various strategies such as partnerships, mergers, reduction in production costs, launching new products, and implementing advanced technologies.

  • On January 27th, 2023, Merck & Co., Inc., a multinational pharmaceutical company, announced that their drug KEYTRUDA had received FDA approval. The approval allows for the use of KEYTRUDA in patients who have undergone surgical resection and platinum-based chemotherapy. The treatment is intended for patients with T2a tumors that are larger than or equal to 4 centimeters in size.

    NTRK Fusion Gene Positive Advanced Solid Tumors Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. NTRK Fusion Gene Positive Advanced Solid Tumors Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. NTRK Fusion Gene Positive Advanced Solid Tumors Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. NTRK Fusion Gene Positive Advanced Solid Tumors Market - Supply Chain
  4.5. Global NTRK Fusion Gene Positive Advanced Solid Tumors Market Forecast
     4.5.1. NTRK Fusion Gene Positive Advanced Solid Tumors Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. NTRK Fusion Gene Positive Advanced Solid Tumors Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. NTRK Fusion Gene Positive Advanced Solid Tumors Market Absolute $ Opportunity
5. Global NTRK Fusion Gene Positive Advanced Solid Tumors Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Types
     5.3.1. Diagnostics
     5.3.2. Therapeutics
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global NTRK Fusion Gene Positive Advanced Solid Tumors Market Analysis and Forecast by Applications
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Applications
     6.2.2. Y-o-Y Growth Projections by Applications
  6.3. NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Applications
     6.3.1. Cancer Centers
     6.3.2. Hospitals
     6.3.3. Clinics
     6.3.4. Others
  6.4. Absolute $ Opportunity Assessment by Applications
  6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global NTRK Fusion Gene Positive Advanced Solid Tumors Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global NTRK Fusion Gene Positive Advanced Solid Tumors Demand Share Forecast, 2019-2026
8. North America NTRK Fusion Gene Positive Advanced Solid Tumors Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Types
     8.4.1. Diagnostics
     8.4.2. Therapeutics
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Applications
     8.7.1. Cancer Centers
     8.7.2. Hospitals
     8.7.3. Clinics
     8.7.4. Others
  8.8. Basis Point Share (BPS) Analysis by Applications
  8.9. Y-o-Y Growth Projections by Applications
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America NTRK Fusion Gene Positive Advanced Solid Tumors Demand Share Forecast, 2019-2026
9. Latin America NTRK Fusion Gene Positive Advanced Solid Tumors Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Types
     9.4.1. Diagnostics
     9.4.2. Therapeutics
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Applications
     9.7.1. Cancer Centers
     9.7.2. Hospitals
     9.7.3. Clinics
     9.7.4. Others
  9.8. Basis Point Share (BPS) Analysis by Applications
  9.9. Y-o-Y Growth Projections by Applications
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America NTRK Fusion Gene Positive Advanced Solid Tumors Demand Share Forecast, 2019-2026
10. Europe NTRK Fusion Gene Positive Advanced Solid Tumors Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Types
     10.4.1. Diagnostics
     10.4.2. Therapeutics
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Applications
     10.7.1. Cancer Centers
     10.7.2. Hospitals
     10.7.3. Clinics
     10.7.4. Others
  10.8. Basis Point Share (BPS) Analysis by Applications
  10.9. Y-o-Y Growth Projections by Applications
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe NTRK Fusion Gene Positive Advanced Solid Tumors Demand Share Forecast, 2019-2026
11. Asia Pacific NTRK Fusion Gene Positive Advanced Solid Tumors Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Types
     11.4.1. Diagnostics
     11.4.2. Therapeutics
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Applications
     11.7.1. Cancer Centers
     11.7.2. Hospitals
     11.7.3. Clinics
     11.7.4. Others
  11.8. Basis Point Share (BPS) Analysis by Applications
  11.9. Y-o-Y Growth Projections by Applications
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific NTRK Fusion Gene Positive Advanced Solid Tumors Demand Share Forecast, 2019-2026
12. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumors Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Types
     12.4.1. Diagnostics
     12.4.2. Therapeutics
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumors Market Size and Volume Forecast by Applications
     12.7.1. Cancer Centers
     12.7.2. Hospitals
     12.7.3. Clinics
     12.7.4. Others
  12.8. Basis Point Share (BPS) Analysis by Applications
  12.9. Y-o-Y Growth Projections by Applications
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumors Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global NTRK Fusion Gene Positive Advanced Solid Tumors Market: Market Share Analysis
  13.2. NTRK Fusion Gene Positive Advanced Solid Tumors Distributors and Customers
  13.3. NTRK Fusion Gene Positive Advanced Solid Tumors Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Bayer AG
     13.4.2. DAIICHI SANKYO COMPANY, LIMITED
     13.4.3. Deciphera Pharmaceuticals, Inc
     13.4.4. F. Hoffmann-La Roche AG
     13.4.5. Glaxosmithkline plc
     13.4.6. Merck & Co., Inc.
     13.4.7. Pfizer Inc.
     13.4.8. Plexxikon

Methodology

Our Clients

Microsoft
Honda Motor Co. Ltd.
Nestle SA
Dassault Aviation
Siemens Healthcare
Deloitte
FedEx Logistics
General Mills